{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:32:37Z","timestamp":1792459957373,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:00:00Z","timestamp":1604620800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.ctrv.2020.102091","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T22:36:05Z","timestamp":1597876565000},"page":"102091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":179,"special_numbering":"C","title":["BAP1: Not just a BRCA1-associated protein"],"prefix":"10.1016","volume":"90","author":[{"given":"Bryan H.","family":"Louie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102091_b0005","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2020.102091_b0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jclinpath-2016-203866","article-title":"Gene of the month: BAP1","volume":"69","author":"Wang","year":"2016","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2020.102091_b0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/PAT.0b013e32835d0efb","article-title":"Tumours associated with BAP1 mutations","volume":"45","author":"Murali","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.ctrv.2020.102091_b0020","unstructured":"Pilarski R, Rai K, Cebulla C, Abdel-Rahman M. BAP1 Tumor predisposition syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews\u00ae, Seattle (WA): University of Washington, Seattle, 1993."},{"key":"10.1016\/j.ctrv.2020.102091_b0025","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/j.jtho.2018.08.204","article-title":"MS31.02 clinical implementation of BAP1 inhibitors","volume":"13","author":"Baas","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0030","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13073-019-0631-0","article-title":"Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma","volume":"11","author":"Ladanyi","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2020.102091_b0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102091_b0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","article-title":"BRCA1\u2013BARD1 promotes RAD51-mediated homologous DNA pairing","volume":"550","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102091_b0050","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2020.102091_b0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2020.102091_b0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2020.102091_b0065","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrm1700","article-title":"Ubiquitin and ubiquitin-like proteins as multifunctional signals","volume":"6","author":"Welchman","year":"2005","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102091_b0070","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1158\/0008-5472.CAN-08-0365","article-title":"BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization","volume":"68","author":"Ventii","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-08255-x","article-title":"BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation","volume":"10","author":"Campagne","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2020.102091_b0080","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nsmb.2669","article-title":"Transcriptional regulation by Polycomb group proteins","volume":"20","author":"Di Croce","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.ctrv.2020.102091_b0085","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dnarep.2015.09.016","article-title":"Histone ubiquitylation and its roles in transcription and DNA damage response","volume":"36","author":"Meas","year":"2015","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.ctrv.2020.102091_b0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13238-010-0010-5","article-title":"The role of BRCA1 in DNA damage response","volume":"1","author":"Wu","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.ctrv.2020.102091_b0095","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.ctrv.2020.102091_b0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molcel.2007.05.030","article-title":"E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases","volume":"27","author":"Tyagi","year":"2007","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2020.102091_b0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.biocel.2015.01.001","article-title":"BAP1 regulates cell cycle progression through E2F1 target genes and mediates transcriptional silencing via H2A monoubiquitination in uveal melanoma cells","volume":"60","author":"Pan","year":"2015","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102091_b0115","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1128\/MCB.00396-10","article-title":"The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression","volume":"30","author":"Yu","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102091_b0120","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1074\/jbc.M114.609834","article-title":"BRCA1-associated Protein 1 (BAP1) deubiquitinase antagonizes the ubiquitin-mediated activation of FoxK2 target genes","volume":"290","author":"Okino","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2020.102091_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0500-6","article-title":"BAP1 induces cell death via interaction with 14\u20133-3 in neuroblastoma","volume":"9","author":"Sime","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ctrv.2020.102091_b0130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","article-title":"BAP1 links metabolic regulation of ferroptosis to tumor suppression","volume":"20","author":"Zhang","year":"2018","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ctrv.2020.102091_b0135","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00262-017-1991-1","article-title":"Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment","volume":"66","author":"Gezgin","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2020.102091_b0140","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/path.5384","article-title":"Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development","volume":"250","author":"Figueiredo","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2020.102091_b0145","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.ctrv.2020.102091_b0150","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102091_b0155","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/ng.910","article-title":"Germline mutations in BAP1 predispose to melanocytic tumors","volume":"43","author":"Wiesner","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102091_b0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamadermatol.2017.2330","article-title":"Genotypic and phenotypic features of BAP1 cancer syndrome","volume":"153","author":"Haugh","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ctrv.2020.102091_b0165","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2020.102091_b0170","doi-asserted-by":"crossref","unstructured":"Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 2016; 89: 285\u201394. Doi: 10.1111\/cge.12630.","DOI":"10.1111\/cge.12630"},{"key":"10.1016\/j.ctrv.2020.102091_b0175","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2020.102091_b0180","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.joco.2018.02.005","article-title":"Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma","volume":"30","author":"Masoomian","year":"2018","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.ctrv.2020.102091_b0185","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1186\/s12885-018-5079-x","article-title":"Comparison of germline versus somatic BAP1 mutations for risk of metastasis in uveal melanoma","volume":"18","author":"Ewens","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102091_b0190","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2020.102091_b0195","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0200","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic landscape of malignant mesotheliomas","volume":"15","author":"Kato","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2020.102091_b0205","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.ctrv.2020.102091_b0210","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.7150\/jca.27281","article-title":"Comprehensive analysis of BAP1 somatic mutation in clear cell renal cell carcinoma to explore potential mechanisms in Silico","volume":"9","author":"Jin","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2020.102091_b0215","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ctrv.2020.102091_b0220","doi-asserted-by":"crossref","DOI":"10.1177\/1758834018757175","article-title":"Treatment of uveal melanoma: where are we now?","volume":"10","author":"Yang","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0225","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","article-title":"Clinical characteristics of Uveal melanoma in patients with germline BAP1 mutations","volume":"133","author":"Gupta","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ctrv.2020.102091_b0230","doi-asserted-by":"crossref","unstructured":"AJ P, V N, A G, K M, G F, R K. GNAS, GNAQ and GNA11 Alterations in Patients with Diverse Cancers. Cancer 2018; 124: 4080\u20139. Doi: 10.1002\/cncr.31724.","DOI":"10.1002\/cncr.31724"},{"key":"10.1016\/j.ctrv.2020.102091_b0235","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","article-title":"Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study","volume":"7","author":"Heppt","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctrv.2020.102091_b0240","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","article-title":"Initial analysis of the international association for the study of lung cancer mesothelioma database","volume":"7","author":"Rusch","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0245","doi-asserted-by":"crossref","unstructured":"G S, H Y, Bm S, D C, Ph S. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000; 87: 1587\u201393. Doi: 10.1046\/j.1365-2168.2000.01571.x.","DOI":"10.1046\/j.1365-2168.2000.01571.x"},{"key":"10.1016\/j.ctrv.2020.102091_b0250","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0255","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0260","doi-asserted-by":"crossref","unstructured":"Research AA for C. Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma. Cancer Discov 2017; 7: OF7\u2013OF7. Doi: 10.1158\/2159-8290.CD-NB2017-087.","DOI":"10.1158\/2159-8290.CD-NB2017-087"},{"key":"10.1016\/j.ctrv.2020.102091_b0265","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0270","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11864-019-0613-x","article-title":"Use of immune checkpoint inhibitors in mesothelioma","volume":"20","author":"Forde","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0275","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaad.2018.05.005","article-title":"Histomorphologic spectrum of germline-related and sporadic BAP1-inactivated melanocytic tumors","volume":"79","author":"Garfield","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctrv.2020.102091_b0280","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/PAS.0b013e3182498be5","article-title":"A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression","volume":"36","author":"Wiesner","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2020.102091_b0285","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/cup.13530","article-title":"BRCA1-associated protein (BAP1)-inactivated melanocytic tumors","volume":"46","author":"Zhang","year":"2019","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.ctrv.2020.102091_b0290","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0295","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","article-title":"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors","volume":"6","author":"Sacco","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2020.102091_b0300","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0305","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2020.102091_b0310","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.7150\/jca.26275","article-title":"EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis","volume":"9","author":"Sun","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2020.102091_b0315","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.8515","article-title":"Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation","volume":"36","author":"Zauderer","year":"2018","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102091_b0320","first-page":"551","article-title":"\u2018BRCAness and its implications for platinum action in gynecologic cancer","volume":"34","author":"Muggia","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0325","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2020.102091_b0330","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.21037\/tlcr.2019.11.24","article-title":"BAP1: role in carcinogenesis and clinical implications","volume":"9","author":"Kobrinski","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0335","doi-asserted-by":"crossref","unstructured":"George TJ, DeRemer DL, Parekh HD, Lee J-H, Markham MJ, Daily KC, et al. Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma. JCO 2020;38:TPS591\u2013TPS591. Doi: 10.1200\/JCO.2020.38.4_suppl.TPS591.","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS591"},{"key":"10.1016\/j.ctrv.2020.102091_b0340","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9054","article-title":"Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes","volume":"38","author":"Hassan","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2020.102091_b0345","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1200\/EDBK_160766","article-title":"Biomarkers for immunotherapy: current developments and challenges","author":"Spencer","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2020.102091_b0350","article-title":"CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma","author":"Zhou","year":"20208","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102091_b0355","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell\u2013mediated killing","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2020.102091_b0360","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/cas.14311","article-title":"Synthetic lethal therapy based on targeting the vulnerability of SWI\/SNF chromatin remodeling complex-deficient cancers","volume":"111","author":"Sasaki","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2020.102091_b0365","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2020.102091_b0370","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000438","article-title":"ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1\/PD-L1 immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2020.102091_b0375","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ng.3734","article-title":"Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states","volume":"49","author":"Kadoch","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102091_b0380","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ng.3735","article-title":"Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin","volume":"49","author":"Stanton","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2020.102091_b0385","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41591-019-0424-4","article-title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","volume":"25","author":"Rodon","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2020.102091_b0390","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41591-019-0407-5","article-title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","volume":"25","author":"Sicklick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2020.102091_b0395","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a Phase I clinical trials program: the MD Anderson cancer center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102091_b0400","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00002","article-title":"Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study","author":"Tsimberidou","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0405","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2020.102091_b0410","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-019-0835-1","article-title":"Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine","volume":"12","author":"Tsimberidou","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2020.102091_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: Evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2020.102091_b0420","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial","author":"Massard","year":"2017","journal-title":"Cancer Discov"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:48Z","timestamp":1759656168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":84,"alternative-id":["S0305737220301298"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102091","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAP1: Not just a BRCA1-associated protein","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102091"}}